{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:42:34Z","timestamp":1761896554953,"version":"3.37.3"},"reference-count":18,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T00:00:00Z","timestamp":1496620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Millennium Pharmaceuticals, Inc."},{"name":"Janssen Global Services, LLC.","award":["LYM-3002"],"award-info":[{"award-number":["LYM-3002"]}]},{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Millennium Pharmaceuticals, Inc"},{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"crossref","award":["LYM-3002"],"award-info":[{"award-number":["LYM-3002"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2019,1,2]]},"DOI":"10.1080\/10428194.2017.1321750","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T06:38:53Z","timestamp":1496731133000},"page":"172-179","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study"],"prefix":"10.1080","volume":"60","clinical-trial-number":[{"clinical-trial-number":"nct00722137","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tadeusz","family":"Robak","sequence":"first","affiliation":[{"name":"Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Beijing Cancer Hospital, Beijing, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[{"name":"West China Hospital of Sichuan University, Chengdu, Sichuan, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Samoilova","sequence":"additional","affiliation":[{"name":"Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russian Federation;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halyna","family":"Pylypenko","sequence":"additional","affiliation":[{"name":"Cherkassy Regional Oncology Dispensary, Cherkassy, Ukraine;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Verhoef","sequence":"additional","affiliation":[{"name":"University Hospital Leuven, Leuven, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noppadol","family":"Siritanaratkul","sequence":"additional","affiliation":[{"name":"Siriraj Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgenii","family":"Osmanov","sequence":"additional","affiliation":[{"name":"Cancer Research Center RAMS \u2013 N.N. Blokhin Academy of Medical Science, Moscow, Russian Federation;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[{"name":"Hospital das Clinicas da Faculdade de Medicina da USP, S\u00e3o Paolo, Brazil;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[{"name":"Faculty Hospital Brno, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Hong","sequence":"additional","affiliation":[{"name":"Fudan University Shanghai Cancer Center, Shanghai, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumiko","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Pei","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, LLC, Raritan, NJ, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Rooney","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, High Wycombe, Buckinghamshire, UK;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helgi","family":"van de Velde","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Cavalli","sequence":"additional","affiliation":[{"name":"Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Ticino, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,6,5]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu264"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12046"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1288"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"CIT0005","unstructured":"Millennium Pharmaceuticals Inc. VELCADE\u00ae (bortezomib) for injection: for subcutaneous or intravenous use. Full prescribing information. October 2014, Revision 17. Available from: http:\/\/www.velcade.com\/files\/pdfs\/velcade_prescribing_information.pdf. 2014."},{"key":"CIT0006","unstructured":"European Medicines Agency (EMA). Velcade 3.5\u2009mg powder for solution for injection: Summary of Product Characteristics. Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/17109. 2015."},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23933"},{"key":"CIT0008","unstructured":"Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. August 2006, Version 3.0. Available from: http:\/\/ctep.cancer.gov. 2006."},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0399-y"},{"key":"CIT0010","first-page":"533","volume":"24","author":"Epelbaum R","year":"1988","journal-title":"Isr Med Assoc J"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900915)66:6<1124::AID-CNCR2820660608>3.0.CO;2-T"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-0956-7"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.6.963"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0447-2"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-28-116"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.51.1"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.5414\/CP202714"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2017.1321750","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2017.1321750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T19:58:18Z","timestamp":1599422298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2017.1321750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,5]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,2]]}},"alternative-id":["10.1080\/10428194.2017.1321750"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2017.1321750","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"type":"print","value":"1042-8194"},{"type":"electronic","value":"1029-2403"}],"subject":[],"published":{"date-parts":[[2017,6,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}